About
Noninvasive Imaging Device for Alzheimer's Disease
SuperSpectra develops a noninvasive imaging device for the early detection and degradation followup of Alzheimer's disease by measuring CSF A and tau quantitative results. The company offers a high-accuracy quantitative measurement with real-time imaging of biomarkers of Alzheimer's disease. This noninvasive direct CSF analysis is ionizing radiation free, pain free, and risk free. Tests can be performed daily/weekly.
Identity
| Name | SuperSpectra |
|---|---|
| Slug | superspectra |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkOKaudAIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Sep 2024 ceased to operate |
| Last update | 2026-05-17 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Technologies
Simulation & Imaging
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business models
B2B2C
Tags
non-invasiveearly-detectionmedical-devicesalzheimers-diseasespectroscopy
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}